3C
PTLA

361 Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

361 Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-44,843
Closed -$1.07M – 418
2019
Q4 		$1.07M Buy
+44,843
New +$1.24M 0.3% 213

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

361 Capital's PTLA Position: Q1 2020 in Review

361 Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2020, closing a stake of 44,843 shares — an estimated $1.07M sold.

361 Capital first reported a position in PTLA in Q4 2019 and held it in 1 quarter. The position peaked at $1.07M in Q4 2019. 187 funds tracked by Wall St. Rank hold PTLA as of Q1 2020.

  • 361 Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2020 after selling out during the quarter.
  • 361 Capital sold 44,843 Portola Pharmaceuticals, Inc. shares in Q1 2020, an estimated $1.07M.
  • 361 Capital first reported a position in Portola Pharmaceuticals, Inc. in Q4 2019 and held it in 1 quarter.
  • 361 Capital's Portola Pharmaceuticals, Inc. position peaked at $1.07M in Q4 2019.
  • 187 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2020.

Based on 361 Capital's 13F filing for Q1 2020, filed 13 May 2020.